Bill St. John

Plus aucun poste en cours

Profil

Bill St John is experienced in strategic intellectual property protection, licensing, university-industry relationships, corporate partnerships, strategic planning, due diligence, venture financing, corporate development and management of diverse teams and operations.
Over the past 25 years, he has started and managed five (5) successful technology companies based on technology licensed or developed at university or government laboratories.
His experience is unique in that each of these ventures utilized very diverse technologies, and targeted different industries.
Each company utilized multi-discipline scientific teams.
Exit strategies for these ventures included public markets, merger and acquisition.
Most recently, Mr. St. John served as CEO of InCode BioPharmaceutics, Inc. InCode is engaged in new drug development using cloning technologies.
As CEO, he completed 3 rounds of venture funding and positioned the company for clinical trials of its drug candidates.
Prior to InCode, Mr. St. John served as CEO of Scolr Parma/ Nutraceutix, Inc., taking the company public and increasing its stock value three-fold.
Scolr developed controlled delivery drug dosage forms using advanced polymer chemistry.
The Nutraceutix division operated a tablet and formulation plant.

Anciens postes connus de Bill St. John

Sociétés	Poste	Fin
InCode BioPharmaceutics, Inc.	Fondateur	-